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Background
Several studies have addressed the relationship of corti-
sone and levels of anxiety. Studies on the influence of
exogenously administered cortisone and levels of anxiety
in the Greek population are lacking.
Materials and methods
We studied 40 patients with bronchial asthma split in 2
groups: in one therapy included cortisone and in the other
not. The two groups did not differ in sex ratio (x2 p >
0.05), age (t test p > 0.05) or duration of disease (t test p
> 0.05), factors that are implicated in generating anxiety.
Anxiety symptoms were assessed with the widely used
Spielberger scale (A-trait).
Results
Mean age of the studied subjects was 42.70 years (SD:
13.69) whereas mean duration of disease was 8.98 (SD:
5.98). For men mean anxiety score was 39.78 (SD: 8.86;
significantly higher than the corresponding value of 34.54
in the general population; t test p < 0.05) whereas for
women mean anxiety score was 44.11 (significantly
higher than the corresponding value of 37.34 in the gen-
eral population; t test p < 0.01). However, no differences
in depressive symptoms were noted between groups (vis-
á-vis cortisone therapy) (t test p > 0.05). Furthermore no
differences were found in the number of subjects that
reported elements of anxiety (x2 p > 0.05).
Discussion
Although bronchial asthma is associated with high levels
of anxiety symptoms the therapeutic use of cortisone does
not appear to contribute in any way in the modulation of
these levels. Nevertheless, it seems necessary to evaluate
the relationship between cortisone and anxiety taking into
account the factor of disease severity, which in clinical
practice appears to be linked to high levels of depression
as well as with the necessity of administering cortisone.
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